Author

P. Vu

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

N. Bardeesy· 2 shared A. Popa· 1 shared C. H. Benes· 1 shared C. L. Oakley-Havens· 1 shared C. R. Ferrone· 1 shared C. Reeves· 1 shared D. E. Root· 1 shared D. Juric· 1 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

N. Bardeesy

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Generation of a biliary tract cancer cell line atlas reveals molecular subtypes and therapeutic targets

V. Vijay, N. Karisani, L. Shi, Y.-H. Hung, P. Vu, P. Kattel, L. Kenney, J. Merritt, R. Adil, Q. Wu, Y. Zhen, R. Morris, J. Kreuzer, M. Kathiresan, X. I. Herrera Lopez, , N. Bardeesy

This study creates a biliary tract cancer cell line atlas using multi-omics data to identify molecular subtypes and therapeutic targets.

bioRxiv · Jul 4, 2024Cancer Biology

Amikacin potentiator activity of zinc complexed to a pyrithione derivative with enhanced solubility

J. Magallon, P. Vu, C. Reeves, S. Kwan, K. Phan, C. L. Oakley-Havens, K. Rocha, V. Jimenez, M. S. Ramirez, M. E. Tolmasky

This paper tests a zinc-pyrithione derivative with improved solubility as an amikacin potentiator against antibiotic-resistant bacteria.

bioRxiv · Oct 8, 2021Microbiology

Oncogenic PKA signaling stabilizes MYC oncoproteins via an aurora kinase A-dependent mechanism

G. K. L. Chan, S. Maisel, Y. C. Hwang, R. R. B. Wolber, P. Vu, K. C. Patra, M. Bouhaddou, H. L. Kenerson, R. S. Yeung, D. L. Swaney, N. J. Krogan, R. E. Turnham, J. D. Scott, K. J. Riehle, N. Bardeesy, J. D. Gordan

This study identifies two PKA-driven oncogenic mechanisms, showing AURKA stabilizes MYC oncoproteins through a PIM2-mediated feedback loop, and suggests CD-532 as a potential therapeutic target.

bioRxiv · Apr 16, 2021Cancer Biology